STOCK TITAN

MetLife (NYSE: MET) director adds 39 deferred shares via dividends

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MetLife Inc. director Laura J. Hay reported an acquisition of 39 shares of MetLife common stock on a Form 4. The shares were credited at a reference price of $85.57 per share through imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, rather than an open-market purchase. Following this routine compensation-related award, Hay directly holds 5,731 MetLife common shares.

Positive

  • None.

Negative

  • None.
Insider Hay Laura J
Role null
Type Security Shares Price Value
Grant/Award Common Stock 39 $85.57 $3K
Holdings After Transaction: Common Stock — 5,731 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares acquired 39 shares Common Stock grant/award acquisition on 2026-06-09
Reference price per share $85.57 per share Imputed dividend reinvestment valuation
Shares held after transaction 5,731 shares Total direct MetLife common stock holdings after award
MetLife Deferred Compensation Plan for Non-Management Directors financial
"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors."
deferred shares financial
"Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred."
Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.
imputed reinvestment of dividends financial
"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hay Laura J

(Last)(First)(Middle)
METLIFE, INC.
200 PARK AVENUE

(Street)
NEW YORK NEW YORK 10166

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/09/2026A(1)39A$85.575,731D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
Remarks:
/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MetLife (MET) director Laura J. Hay report?

Laura J. Hay reported receiving 39 MetLife common shares. The shares were credited as a compensation-related award through dividend reinvestment, not bought in the open market, and increased her direct holdings to 5,731 shares.

At what price were the 39 MetLife (MET) shares attributed to Laura J. Hay?

The 39 MetLife shares were attributed at a reference price of $85.57 per share. This figure reflects the price used for the imputed dividend reinvestment under the company’s deferred compensation plan for non-management directors.

How many MetLife (MET) shares does Laura J. Hay hold after this Form 4 transaction?

After the reported transaction, Laura J. Hay directly holds 5,731 MetLife common shares. This total includes the 39 shares credited via dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors.

Was Laura J. Hay’s MetLife (MET) share acquisition an open-market purchase?

No, the acquisition was not an open-market purchase. The 39 MetLife shares were credited through imputed reinvestment of dividends on deferred shares under a non-management directors’ deferred compensation plan, making it a routine compensation-related award.

What is the MetLife Deferred Compensation Plan for Non-Management Directors?

The MetLife Deferred Compensation Plan for Non-Management Directors allows directors to defer receipt of payable shares. In this case, dividends on deferred shares were imputed as additional MetLife common shares credited to Laura J. Hay’s deferred compensation account.